SEC Form 4 · accession 0000880771-15-000009

SCICLONE PHARMACEUTICALS INC · SCLN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Feb 12, 2015

Accepted (ET)

Feb 13, 2015 · 4:28 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000880771

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Feb 12, 2015	M	12,352	$5.10	A	37,392	D
Common Stock^F1	Feb 12, 2015	M	16,667	$5.22	A	54,059	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Non-Qualified Stock Options (right to buy)^F2,F3	$5.10	Feb 12, 2015	M	12,352	D	—	Jun 12, 2024	Non-Qualified Stock Options (right to buy)	12,352	7,648	D
Non-Qualified Stock Options (right to buy)^F2,F4	$5.22	Feb 12, 2015	A	16,667	D	—	Sep 17, 2023	Non-Qualified Stock Options (right to buy)	16,667	33,333	D

F1Includes 25,040 shares indirectly held by partnership.
F2Granted under the Issuer's 2005 Equity Incentive Plan.
F3Each option shall vest and become exercisable at the rate of one-twelfth of the shares subject to the option at the end of each one-month period from the date of grant except that, in the event of a change in control, any unexercisable or unvested portions of outstanding options shall be immediately exercisable and vested in full as of the date ten (10) days prior to the change in control, regardless of whether the option is assumed or substituted for by the acquirer.
F4Shares will become exercisable in three equal annual installments beginning on the first anniversary of the date of grant, subject to the Outside Director's continuous service on Issuer's Board of Directors.